Medicilon Won Praise and Awards From Many Partners

2022-02-28

Page View：

Leading Tac Pharma's PROTAC drug project is a first-in-class research and development project that challenges anti-tumor and autoimmune diseases. In the cooperation with Medicilon, the Medicilon's DMPK team actively communicated with Leading Tac which helped customers solve a series of research and development problems such as large molecular weight, ensuring the completion of the project. Leading Tac awarded Medicilon the "Best Medicinal Chemistry Partner Team Award", "Best Biological DMPK Partner Team Award", "Best Biological DMPK Partner Individual Award", etc., affirming the cooperation with Medicilon.

❖ Medicilon Discovery Chemistry PROTAC Platform

Medicilon’s PROTAC drug discovery technology platform covers the currently popular target protein ligands. Medicilon has established a linker system with an extensive collection of bifunctional linkers. Together with our expanding E3 ubiquitin ligase binder library, Medicilon can efficiently synthesize a substantial amount of highly active PROTAC bispecific small molecules, which would have the potential to significantly facilitate the drug discovery and development process. In addition, Medicilon has established as well as improved the PROTAC biological screening and testing platform throughout the pre-clinical stages.

Reference:
In Vitro Evaluation of PROTAC Molecules
CGeneTech and Medicilon Held the Conference Titled “PROTAC Project Contract Signing & Kick-off Meeting”

At the same time, the Medicilon's FTE team also received customer awards. The Medicilon FTE team uses a flexible cooperation to meet the diverse R&D needs of customers. From target confirmation, compound optimization, compound screening, druggability research and other stages of drug discovery, saving the time and cost of customers.

Medicilon's awards.webp

Medicilon's awards-1.webp

ABM Therapeutics has cooperated with Medicilon since 2016. During the six-year cooperation, customers have been satisfied with the service quality of FTE. In 2021, Medicilon was awarded the "Best Service Team Award". During the cooperation period, Medicilon FTE also helped ABM Therapeutics discover the clinical candidate compound (PCC) ABM-1310 (the drug is currently undergoing clinical trials in China and the United States simultaneously).

❖ Medicilon’s FTE/FFS services

In the early stages of new drug development, FTE (Full-time equivalent) is often used by drug discovery companies to synthesize the required structural fragments and/or potential candidate compounds to accelerate the drug screening process.

Medicilon provides comprehensive chemistry research services covering all stages of your project requirements, and customers can cooperate with us through the FFS (Fee for Service) or FTE (Full-time Equivalent Service) models. Medicilon FTE/FFS service scope covers medicinal chemistry, synthetic chemistry, analytical chemistry.

The client, MindRank, is an AI pharmaceutical company. In the cooperation with Medicilon’s FTE, it has given full play to the advantages of AI design combined with laboratory confirmation. In a short-term, low-cost and high-efficiency working mode, Medicilon completed the cooperative project with high quality, and was awarded the "2021 Excellent Team Award" by the customer.

In addition to the above-mentioned awards, Medicilon has recently been awarded the "Excellence in Service Award of 2021" by Kumquat Biosciences, the "Excellent Performance Award" by Jemincare, and the "Best Cooperation "Partner", "Best Contribution Award", "Best Partner" awarded by Medilink Therapeutics, etc.

Protac FTE Leading-Tac ABM-Therapeutics

Return

Relevant News

ABM Therapeutics presented Medicilon with a commemorative trophy of "our first candidate compound"

2020-10-31

On October 31, 2020, ABM Therapeutics awarded the "Our First Candidate Compound" commemorative trophy to Dr. Li Zhigang, Vice President of Research and Development of Medicilon Chemistry Department, to thank Medicilon for its FTE form of cooperation, the pharmaceutical and chemical team helped it discover and advance the first drug candidate ABM-1310 to enter the clinical phase I in the United States.

Medicilon Assists ABM Therapeutics to Obtain US FDA Orphan Drug Qualification for ABM-1310 for the Treatment of Patients with Brain Glioblastoma Carrying BRAF V600 Mutation

2023-08-24

ABM Therapeutics announced that its self-developed small molecule BRAF inhibitor ABM-1310 has obtained orphan drug qualification from the US FDA for the treatment of BRAF V600 mutant brain glioblastoma (GBM). Medicilon provided drug discovery services in a flexible cooperation mode.